Table 2

Level of circulating microparticles (MPs), secretory phospholipase A2 (sPLA2), sCD40L, sCD62P in patients with primary Sjögren syndrome (pSS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and in healthy controls (HCs)

pSS

SLE

RA

HC

MP level by capture assay, nM PS Eq

Total MPs (n)

8.49 ± 1.14 (43)

7.3 ± 1.25 (20)

7.23 ± 1.05 (26)

4.13 ± 0.2 (44)

Platelet GPIb+ MPs (n)

4.89 ± 1.25 (40)

4.28 ± 0.36 (18)

4.86 ± 1.48 (24)

1.12 ± 0.11 (18)

Leukocyte CD11a+ MPs (n)

5.78 ± 0.37

(40)

3.89 ± 0.4

(17)

4.28 ± 0.9

(21)

3.92 ± 0.21

(44)

MP number/μL plasma by FACS

Total MPs (n)

91,700 ± 31,292 (5)

71,230 ± 19,160 (4)

127,200 ± 46,825 (2)

6422 ± 3472

(5)

Platelet CD61+ MPs (n)

48,930 ± 18,260 (4)

32,290 ± 17,250 (4)

94370 ± 46,584 (2)

4229 ± 3914 (4)

Leukocyte CD45+ MPs (n)

927 ± 729

(4)

422 ± 149

(4)

304 ± 33

(2)

190 ± 100

(4)

sPLA2 activity, nmol/min/mL (n)

50.9 ± 3.5

(37)

60.7 ± 8.0

(17)

69.8 ± 9.3

(25)

41.8 ± 3.4

(28)

sCD40L, pg/mL (n)

233 ± 31.7 (33)

262.6 ± 63.9 (17)

345.7 ± 67.23 (25)

133.6 ± 4.8 (33)

sCD62P, ng/mL (n)

38.9 ± 2.5 (34)

39.3 ± 3.7 (16)

43.4 ± 3.0 (25)

23.0 ± 1.0 (32)

Results are expressed as mean ± standard error of the mean. The number of patients tested is indicated in each box (n).

Sellam et al. Arthritis Research & Therapy 2009 11:R156   doi:10.1186/ar2833